Welcome to our dedicated page for BIODESIX news (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on BIODESIX stock.
Biodesix Inc (BDSX) delivers innovative diagnostic solutions through advanced blood-based testing for lung disease and oncology. This news hub provides investors and healthcare professionals with essential updates on corporate developments, clinical advancements, and strategic partnerships.
Access real-time updates on earnings announcements, FDA clearances, clinical trial results, and biopharmaceutical collaborations. Our curated collection ensures you stay informed about critical developments in molecular diagnostics and precision medicine without needing to track multiple sources.
Key updates include:
• Financial performance reports
• Diagnostic test approvals
• Research partnership announcements
• Clinical study outcomes
Bookmark this page for streamlined access to verified Biodesix news. Combine regular monitoring with in-depth analysis of how these developments impact the diagnostic solutions landscape.
Rhea-AI Summary
Biodesix, Inc. (BDSX) presented new data at the AACR Annual Meeting 2024 showcasing advancements in liquid biopsy technologies for detecting cell-free DNA and the importance of rapid turnaround time in identifying actionable tumor mutations in a real-world clinical setting. The studies included a presentation on single cell and cell-free nucleic acid analyses using a new droplet digital PCR system, as well as real-world assessment of turnaround time for variant testing in NSCLC. An exploratory analysis from the FLAURA2 clinical study sponsored by AstraZeneca was also presented, focusing on the prognostic and predictive nature of EGFR mutations in patients with EGFR-mutated advanced NSCLC receiving first-line osimertinib treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
-
Rhea-AI Summary
Biodesix, Inc. (BDSX) announces the pricing of its underwritten offering of common stock and concurrent private placement, expecting gross proceeds of $55.0 million. The company plans to convert Series A Non-Voting Convertible Preferred Stock to common stock upon stockholder approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.28%
Tags
-
Rhea-AI Summary
Biodesix, Inc. (BDSX) has signed a new master collaborative research agreement with Memorial Sloan Kettering Cancer Center to develop diagnostic tests for cancer treatment. The collaboration aims to create oncology biomarker assays utilizing Biodesix's genomics, proteomics, and data mining capabilities, along with Bio-Rad's digital PCR assay technology. This partnership marks a significant milestone for Biodesix in the field of oncology diagnostics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
Rhea-AI Summary
Biodesix, Inc. (BDSX) reports impressive financial and operational results for the fourth quarter and fiscal year 2023, showcasing significant growth in Lung Diagnostic test volume, gross profit margin improvement, and strong revenue guidance for 2024. The company achieved a 65% increase in Lung Diagnostic test volume in FY2023, with a 77% gross profit margin in Q4 2023. Total revenue for Q4 2023 was $14.7 million, representing a 52% increase year-over-year. Biodesix anticipates generating $65 to $68 million in total revenue in 2024, indicating a 32% to 39% growth rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
-
Rhea-AI Summary
Biodesix, Inc. (BDSX) CEO, Scott Hutton, will present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024. The presentation will focus on the company's diagnostic solutions for lung disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
-
Rhea-AI Summary
Biodesix, Inc. (BDSX) will release financial results for Q4 and year-end 2023 on March 1. A conference call and webcast will follow to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.73%
Tags
Rhea-AI Summary
Biodesix, Inc. (Nasdaq: BDSX) announced the validation and launch of a new method of collecting blood specimens for Nodify Lung Nodule Risk Assessment testing. This method uses the FDA-cleared Tasso+™ device, enabling capillary blood draws for healthcare providers without convenient access to phlebotomy services or licensed phlebotomists. The device was validated to be administered in minutes, creating efficiencies in the Nodify Lung workflow. Biodesix received approval from the New York State Clinical Laboratory Evaluation Program to use the Tasso+ device as a specimen collection method in support of Nodify Lung testing after entering into a supply agreement with Tasso, Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
-
Rhea-AI Summary
Biodesix, Inc. (Nasdaq: BDSX) to participate in Canaccord Genuity Medtech, Diagnostics, Digital Health & Services Forum and Piper Sandler 35th Annual Healthcare Conference. CEO Scott Hutton to present and hold 1x1 meetings. Webcast available for replay on company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.39%
Tags
-
Rhea-AI Summary
BDSX Q3 2023 Financial Results: 60% Lung Diagnostic test volume growth, 76% gross profit margin, $10.9M net loss, and $5.4M Adjusted EBITDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.14%
Tags
Rhea-AI Summary
Biodesix, Inc. (Nasdaq: BDSX) will release financial results for Q3 2023 on November 7. A conference call and webcast will be held to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
BIODESIX INC
Nasdaq:BDSX
BDSX Rankings
BDSX Stock Data
80.14M
68.04M
48.45%
40.21%
0.67%
Diagnostics & Research
Services-medical Laboratories
United States
LOUISVILLE